Amylyx Pharmaceuticals Stock
Amylyx Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Joshua Cohen
- Employees
- 136
- Market cap
- $3.3 B
- IPO
- 07/01/2022
- Web
- amylyx.com
Amylyx Pharmaceuticals, Inc. is a clinically-oriented healthcare and biotechnology company headquartered in Cambridge, Massachusetts. Since its founding in 2013, the U.S.-based firm has focused primarily on developing novel therapies for amyotrophic lateral sclerosis (ALS) as well as other neurodegenerative diseases.…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Amylyx Pharmaceuticals stock: price history
1D
-4.7%
1W
-6.4%
1M
-19.3%
6M
+43.5%
YTD
+118.0%
1Y
+73.6%
2Y
+545.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~2% stronger price swings than usual
Amylyx Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's cornerstone is the proprietary drug candidate AMX0035, a dual UPR-Bax apoptosis inhibitor. The company currently generates no revenue from product sales as it remains in the research phase.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Amylyx Pharmaceuticals
Analyst assessment of Amylyx Pharmaceuticals
PRICE TARGET LOW
US$42.00
CONSENSUS
US$52.20
MEDIAN
US$55.00
PRICE TARGET HIGH
US$57.00
0
STRONG BUY
10
BUY
1
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 15/10/2026
Amylyx Pharmaceuticals stock metrics
P/E
-18.68
P/B
12.25
EV/EBITDA
-21.78
RETURN ON EQUITY
-18.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.6%
FLOAT SHARES
97,276,778
AVG. DAILY VOLUME (30D)
1,400,933
Insider transactions (SEC)
MILNE GEORGE M JR
Klee Justin B.
Klee Justin B.
Cohen Joshua B
Cohen Joshua B
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.7%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Amylyx Pharmaceuticals stock
What does Amylyx Pharmaceuticals do?
Amylyx Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Joshua Cohen, the company employs around 136 people.
The IPO was on 07/01/2022; the stock trades on NASDAQ under the ticker AMLX.
What do analysts say about Amylyx Pharmaceuticals stock?
11 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$52.20, ranging from US$42.00 to US$57.00, with a median of US$55.00.
This is an external assessment, not a statement by Market Jury.
When does Amylyx Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Amylyx Pharmaceuticals pay a dividend?
Yes. The last dividend was US$0.42 per share, ex-date 28/03/2018, paid on 02/04/2018.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Amylyx Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Amylyx Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Amylyx Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.